Oncology Pharma, Inc. Addresses Pancreatic Cancer, The Need For An Effective Therapy And The Potential of mRNA
Source: InvestorsHub NewsWire
San Francisco, CA -- April 14, 2021 -- InvestorsHub NewsWire -- Oncology Pharma Inc. (OTC: ONPH) On April 7, 2021 Oncology Pharma, Inc. ( the "Company") reported that it had been granted an exclusive worldwide license by Regen BioPharma, Inc. to develop and commercialize pancreatic cancer treatments utilizing Regen's proprietary intellectual property pertaining to mRNA.
A Spokesperson for the Company, today expanded on the reasons for obtaining this license stating:
"Pancreatic Cancer is one of the most lethal forms of cancer ranking as the fourth leading cause of cancer deaths in the United States. The median survival duration from diagnosis until death for untreated advanced pancreatic cancer is approximately 3 1/2 months; increasing to about eight months with treatment.
mRNA vaccines have become a promising platform for cancer immunotherapy. The intellectual property which we licensed from Regen encompasses an exciting method of utilizing mRNA to cause changes in the cancer cells which would stimulate the patient's own immune response to battle this deadly disease.
According to the National Cancer Institute more than 1.7 million new cases of pancreatic cancer emerge in the United States per year resulting in 609,604 deaths. The cost of treating pancreatic cancer in the United States is $174 billion per year and growing. These are staggering numbers.
We believe that developing a solid therapy to treat this disease is our mission. We want to help save lives and bring hope where currently little hope exists. We believe our mRNA based pancreatic cancer therapies will prove dynamic and powerful."
The Spokesperson further noted "We are more than a biotechnology company. We believe our shareholders expect us to not only develop therapies that improve lives but to develop therapies that save lives. Knowing what we know about pancreatic cancer, this is a great cornerstone on which to focus our Company's research activities."
